Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

"Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment" was originally created and published by Clinical ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

View full profile. Learn about our editorial policies. The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi ...

a phenomenon called RNA interference or RNAi. The apparently widespread nature of RNAi in eukaryotes, ranging from trypanosome to mouse, has sparked great interest from both applied and ...

Gómez, Isaura Torres Ruiz, Orville Hernandez Muñoz, Jose F. Garcia, Ana María Restrepo, Angela and McEwen, Juan G. 2013. RNAi technology targeting Pb<i>GP</i>43 and ...